RxDoctor Payments Data

Monica Lynam

Adult Health · Las Vegas, NVNPI 1902511496

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 38.3% of the total.

$5,428in general payments, 2019–2025

Across 241 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • AbbVie$663
  • Merck$545
  • Shionogi Inc$327
  • Astellas Pharma US Inc$265
  • plus $513 from 10 others

What the payments were for

  • Food & beverage$5,29898%
  • Education$1302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,428 in reported general payments places this provider in the 85th percentile of 90 adult health providers in Nevada.

See all adult health providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala224$913,441
DovatoDolutegravir Sodium/Lamivudine62$185,103
TriumeqAbacavir/Dolutegravir/Lamivudi16$79,041
DelstrigoDoravirine/Lamivu/Tenofov Diso14$37,462
DescovyEmtricitabine/Tenofov Alafenam12$29,175
VemlidyTenofovir Alafenamide13$18,807
Fosfomycin Tromethamine18$3,361
Tenofovir Disoproxil Fumarate19$2,736
Rifampin30$1,891
Azithromycin31$1,181
Ethambutol Hcl14$873
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav42$661
Cephalexin13$594
Fluconazole19$362
Isoniazid51$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Vemlidy$1,036$961,424249 claims
Viiv Healthcare CompanyDovato, Triumeq$2,079$264,14578 claims
MerckDelstrigo$545$37,46214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 adult health providers in Nevada.

Other adult health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →